Mass Spectrometry Regulated Bioanalytical Advances for Biomarkers

Ligand binding assays (LBAs) are essential for protein biomarker quantification but are limited by their reliance on critical reagents, variable specificity, and vulnerability to cross-reactivity. Historically, LC–MS was viewed as lower throughput and more technically complex. Recent advances including single-day sample preparation, preset high-throughput LC methods, reduced matrix interference through SEC or immunocapture, and improved sensitivity with HRMS PRM and next-generation MS are overcoming these challenges.

This presentation uses targeted case studies to challenge legacy perceptions, showing how Context-of-Use (COU) aligned LC–MS workflows now consistently deliver selective, sensitive, and reproducible biomarker data suitable for regulated decision-making, often as a complement or orthogonal validation to LBAs. Mass spectrometry based biomarker quantification is advancing rapidly, aided by harmonized validation frameworks like ICH M10 and clearer COU guidance, which are reshaping expectations for regulated bioanalysis. These developments, along with major technology gains, now position LC–MS as a practical, decision-driving platform for a range of biomarker classes.

Recent chromatography improvements—especially low-flow nano/microflow LC systems—enable high-throughput workflows with cycle times of eight minutes or less, maintaining retention-time stability and pg/mL sensitivity. New hardware minimizes analyte loss for low-abundance proteins and peptides by reducing adsorption and eliminating lengthy conditioning steps. Sample preparation has evolved: tasks that once took days now finish within hours. Automation-ready immunocapture platforms and magnetic-bead processing enhance reproducibility and throughput.

The presentation demonstrates how COU-aligned strategies optimize LC–MS biomarker assays for regulated environments, leveraging accelerated workflows. Case studies include rapid quantification of soluble protein biomarkers (e.g., TL1A), sensitive multiplexed peptide-hormone assays, and multidimensional approaches like SEC to reduce matrix complexity. The session also highlights the expanding role of high-resolution MS in achieving attomole sensitivity and broad dynamic range, supporting emerging COUs, complex biologics, and precision medicine research.